Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Thymalfasin · TA1 · Zadaxin
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Immunomodulatory peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Modulates immune-cell responses; “immune boosting” is not a defined clinical endpoint.
Evidence and critical reading
Reported scientific and empirical uses
Immune modulation and inflammation
Handbooks associate it with infection, hepatitis and oncology support. Each context requires local authorization and clinical-outcome evidence; tolerability alone does not demonstrate benefit.
Human evidence
TESTS phase III did not demonstrate lower 28-day sepsis mortality; retain its linked correction. Historical hepatitis findings address different populations.
Preclinical evidence
Immune signaling cannot establish prevention of infections or cancer in healthy people.
Critical reading and limitations
TESTS, a phase III sepsis trial enrolling 1,106 participants, did not show reduced 28-day mortality. It does not settle every possible use, but it cannot support a general immune-benefit claim. Retain its correction and distinguish trial from handbook regimens.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
1.5 mg · Amount per administration
- Frequency
- Every third day per source.
- Duration
- Source varies duration by disease; no general cycle established.
- Route
- Subcutaneous
- Context
- Broad immune uses described; indications not verified by that page.
- Presentation
- 3 mg/mL; 5-mL vial, per source.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 150 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US compounding assessment is not FDA approval. National approvals outside US/EU require the local label; not verified here.
Adverse effects and unknowns
No blanket safety conclusion; distinguish trial adverse events from theoretical concern with immune-modifying drugs.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID39814420 · Randomized placebo-controlled phase III
Adults with sepsis; 1,089 in modified analysis.
Subcutaneous every 12 h, up to 7 days.
28-day mortality: 23.4% versus 24.1%; no significant difference.
Do not generalize to every immune disorder; retain correction PMID40447307.
n = 1106
Trials attributed in the package
NCT02867267 · The Efficacy and Safety of Ta1 for SepsisRegistry status: CompletedLast update posted: April 10, 2023Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Thymosin α1 · 13 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07675980 · Thymosin-α1 for Recurrent Implantation FailureRegistry status: RecruitingLast update posted: October 15, 2026Query verification: October 16, 2026
NCT05339529 · Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)Registry status: CompletedLast update posted: September 14, 2026Query verification: October 16, 2026
NCT06139419 · The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLCRegistry status: CompletedLast update posted: August 3, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID39814420
Wu J, Pei F, Zhou L, Li W, Sun R, Li Y, Wang Z, He Z, Zhang X, Jin X, Long Y, Cui W, Wang C, Chen E, Zeng J, Yan J, Lin Q, Zhou F, Huang L, Shang Y, Duan M, Zheng W, Zhu D, Kou Q, Zhang S, Liu Y, Yao C, Shang M, Peng S, Zhou Q, Cheng KK, Guan X, TESTS study collaborator group.
October 16, 2026
- PMID40447307
October 16, 2026
- R06
- R16
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026